Table 5
Summary of the selected univariate meta-regression results based on different estimation techniques using each study characteristic variable as a moderator to explain the extra heterogeneity present in infarct volume data
| Method | Variable | Estimate (SE/MC error) | 95% Cl | P value | τ2 | I2 (%) | R2 (%) |
| REML | No covariate | 35.5 (2.35) | 30.8 to 40.2 | <0.0001 | 213.9 | 82.40 | |
| Time to outcome measure (intercept) | 37.7 (2.75) | 32.3 to 43.2 | <0.0001 | 206.4 | 80.80 | 3.50 | |
| Time to outcome measure | −0.03 (0.02) | −0.06 to 0.01 | 0.12 | ||||
| Route of drug delivery (intercept) | 31.5 (3.27) | 24.9 to 38.0 | <0.0001 | 120.1 | 69.60 | 43.90 | |
| Route of delivery (intracerebroventricular) | 20.3 (5.54) | 9.25 to 31.4 | 0.001 | ||||
| Route of drug delivery (other) | −14.6 (5.67) | −26.0 to −3.31 | 0.01 | ||||
| Route of drug delivery (intravenous) | 5.79 (4.99) | −4.19 to 15.8 | 0.25 | ||||
| Dose (intercept) | 38.0 (2.91) | 32.2 to 43.8 | <0.0001 | 221.9 | 81.70 | 0 | |
| Dose | −0.02 (0.02) | −0.05 to 0.01 | 0.17 | ||||
| DL | No covariate | 35.7 (2.35) | 31.0 to 40.4 | <0.0001 | 235.2 | 83.70 | |
| Time to outcome measure (intercept) | 38.0 (2.75) | 32.5 to 43.5 | <0.0001 | 253.3 | 83.80 | 0 | |
| Time to outcome measure | −0.03 (0.02) | −0.06 to 0.01 | 0.13 | ||||
| Route of drug delivery (intercept) | 32.4 (3.31) | 25.8 to 39.1 | <0.0001 | 177.8 | 77.20 | 24.40 | |
| Route of delivery (intracerebroventricular) | 19.3 (5.49) | 8.28 to 30.3 | 0.001 | ||||
| Route of drug delivery (other) | −15.5 (5.99) | −27.4 to −3.50 | 0.01 | ||||
| Route of drug delivery (intravenous) | 4.48 (5.02) | −5.57 to 14.5 | 0.38 | ||||
| Dose (intercept) | 38.4 (2.91) | 32.5 to 44.2 | <0.0001 | 263.5 | 84.20 | 0 | |
| Dose | −0.02 (0.02) | −0.05 to 0.01 | 0.15 | ||||
| Bayesian | No covariate | 35.5 (0.03) | 30.3 to 40.7 | <0.0001 | 224.2 | ||
| Time to outcome measure (intercept) | 37.6 (0.05) | 31.7 to 37.6 | <0.0001 | 215.2 | |||
| Time to outcome measure | −0.03 (0.0004) | −0.07 to 0.01 | 0.14 | ||||
| Route of drug delivery (intercept) | 31.5 (0.10) | 24.4 to 39.3 | <0.0001 | 127.7 | |||
| Route of delivery (intracerebroventricular) | 20.2 (0.15) | 7.78 to 32.3 | 0.002 | ||||
| Route of drug delivery (other) | −14.6 (0.12) | −27.7 to −1.99 | 0.03 | ||||
| Route of drug delivery (intravenous) | 5.85 (0.13) | −5.50 to 16.9 | 0.31 | ||||
| Dose (intercept) | 37.9 (0.06) | 31.7 to 44.7 | <0.0001 | 232.9 | |||
| Dose | −0.02 (0.0003) | −0.0 to 0.01 | 0.17 |
P values are calculated based on Wald-type test statistics and mako. Associated full tables can be found in the Appendix (https://osf.io/6usxq/) (
, ).DL, DerSimonian and Laird; MC, Monte Carlo; REML, restricted maximum likelihood.
